Renal Denervation in Patients With Refractory Hypertension (HTN-1)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Symplicty(TM) Catheter System
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- >= 18 years of age
- a systolic blood pressure of 160mmHg or more
- receiving and adhering to full doses of at least three antihypertensive drugs
- estimated glomerular filtration rate (eGFR) of ≥45mL/min
- agrees to have the study procedure(s) performed and additional procedures and evaluations
- is competent and willing to provide written, informed consent to participate in this clinical study
Exclusion Criteria:
- hemodynamically or anatomically significant renal artery stenosis
- has a history or prior renal artery angioplasty
- has experienced MI, unstable angina pectoris, or CVA within 6 months
- has hemodynamically significant valvular heart disease
- has Type 1 diabetes
- has an implantable cardioverter defibrillator (ICD) or pacemaker, or any other metallic implant which is not compatible with magnetic resonance imaging (MRI)
- requires respiratory support
- is pregnant, nursing, or planning to be pregnant
- has known, unresolved history of drug use or alcohol dependency.
- is currently enrolled in another investigational drug or device trial.
Sites / Locations
- Herzzentrum Bad Krozingen
- St. Elisabeth Hospital
- Klinikum Coburg
- Universitaetsklinikum Duesseldorf
- University of Erlangen at Nuremburg
- CardioVascular Center Frankfurt, Sankt Katharinen
- Clinical Trial Center North
- Universitatskliniken des Saarlandes
- University of Leipzig - Herzzentrum
Outcomes
Primary Outcome Measures
To document that renal denervation achieved via the delivery of RF energy is safe, and not associated with clinically significant adverse events, in patients with refractory hypertension.
Secondary Outcome Measures
To document the physiologic effects of renal denervation in patients with refractory hypertension.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00664638
Brief Title
Renal Denervation in Patients With Refractory Hypertension
Acronym
HTN-1
Official Title
Renal Denervation in Patients With Refractory Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Vascular
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Symplicty(TM) Catheter System
Intervention Description
Renal denervation using the Symplicity Catheter System
Primary Outcome Measure Information:
Title
To document that renal denervation achieved via the delivery of RF energy is safe, and not associated with clinically significant adverse events, in patients with refractory hypertension.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
To document the physiologic effects of renal denervation in patients with refractory hypertension.
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
>= 18 years of age
a systolic blood pressure of 160mmHg or more
receiving and adhering to full doses of at least three antihypertensive drugs
estimated glomerular filtration rate (eGFR) of ≥45mL/min
agrees to have the study procedure(s) performed and additional procedures and evaluations
is competent and willing to provide written, informed consent to participate in this clinical study
Exclusion Criteria:
hemodynamically or anatomically significant renal artery stenosis
has a history or prior renal artery angioplasty
has experienced MI, unstable angina pectoris, or CVA within 6 months
has hemodynamically significant valvular heart disease
has Type 1 diabetes
has an implantable cardioverter defibrillator (ICD) or pacemaker, or any other metallic implant which is not compatible with magnetic resonance imaging (MRI)
requires respiratory support
is pregnant, nursing, or planning to be pregnant
has known, unresolved history of drug use or alcohol dependency.
is currently enrolled in another investigational drug or device trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henry Krum, PhD
Organizational Affiliation
Monash University and The Alfred Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Herzzentrum Bad Krozingen
City
Bad Krozingen
Country
Germany
Facility Name
St. Elisabeth Hospital
City
Bochum
Country
Germany
Facility Name
Klinikum Coburg
City
Coburg
Country
Germany
Facility Name
Universitaetsklinikum Duesseldorf
City
Duesseldorf
Country
Germany
Facility Name
University of Erlangen at Nuremburg
City
Erlangen
Country
Germany
Facility Name
CardioVascular Center Frankfurt, Sankt Katharinen
City
Frankfurt
Country
Germany
Facility Name
Clinical Trial Center North
City
Hamburg
Country
Germany
Facility Name
Universitatskliniken des Saarlandes
City
Homburg
Country
Germany
Facility Name
University of Leipzig - Herzzentrum
City
Leipzig
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
24210779
Citation
Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014 Feb 15;383(9917):622-9. doi: 10.1016/S0140-6736(13)62192-3. Epub 2013 Nov 7. Erratum In: Lancet. 2014 Feb 15;383(9917):602. Sobotka, Paul A [added].
Results Reference
derived
PubMed Identifier
23780578
Citation
Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Bohm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013 Jul 9;128(2):132-40. doi: 10.1161/CIRCULATIONAHA.112.000949. Epub 2013 Jun 18. Erratum In: Circulation. 2014 May 20;129(20):e502.
Results Reference
derived
PubMed Identifier
21518978
Citation
Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011 May 10;123(18):1940-6. doi: 10.1161/CIRCULATIONAHA.110.991869. Epub 2011 Apr 25.
Results Reference
derived
PubMed Identifier
19332353
Citation
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28.
Results Reference
derived
Learn more about this trial
Renal Denervation in Patients With Refractory Hypertension
We'll reach out to this number within 24 hrs